EntryPoint Capital’s Ocular Therapeutix OCUL Stock Holding History

EntryPoint Capital’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$330K	Buy	38,994 +26,989	+225%	+$257K	0.1%	431
2025 Q4	$146K	Hold	12,005	–	–	0.06%	593
2025 Q3	$140K	Sell	12,005 -12,257	-51%	-$147K	0.05%	596
2025 Q2	$225K	Sell	24,262 -17,769	-42%	-$139K	0.11%	421
2025 Q1	$308K	Buy	+42,031	New	+$323K	0.14%	307
2024 Q2	–	Sell	-15,312	Closed	-$139K	–	1412
2024 Q1	$139K	Buy	+15,312	New	+$109K	0.12%	257

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

EntryPoint Capital's OCUL Position: Q1 2026 in Review

EntryPoint Capital increased its Ocular Therapeutix (OCUL) stake by 225% in Q1 2026, buying an estimated $257K and bringing the position to 38,994 shares worth $330K. The position accounts for 0.1% of the portfolio, ranked #431.

EntryPoint Capital first reported a position in OCUL in Q1 2024 and has held it in 6 quarters since. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

EntryPoint Capital held 38,994 shares of Ocular Therapeutix worth $330K as of Q1 2026.
EntryPoint Capital bought 26,989 Ocular Therapeutix shares in Q1 2026, an estimated $257K.
Ocular Therapeutix made up 0.1% of EntryPoint Capital's portfolio in Q1 2026, its #431 holding.
EntryPoint Capital first reported a position in Ocular Therapeutix in Q1 2024 and has held it in 6 quarters since.
269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.